C-C motif chemokine 17 Antibodies

C-C motif chemokine 17 (CCL17)

Chemotactic element for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells.

Binds to CCR4. .

Gene Information

Human
Gene Name:	CCL17
Uniprot:	Q92583
Entrez:	6361

Family

Belongs to:
intercrine beta (chemokine CC) family

Alternative Names

ABCD-2; CC chemokine TARC; C-C motif chemokine 17; CCL17; chemokine (C-C motif) ligand 17; MGC138273; SCYA17; SCYA17MGC138271; small inducible cytokine subfamily A (Cys-Cys), member 17; Small-inducible cytokine A17; T cell-directed CC chemokine; TARC; TARCA-152E5.3; Thymus and activation-regulated chemokine

Molecular Weight

Mass (kDA):
10.507 kDA

Genomic Context

Human
Location:	16q21
Sequence:	16; NC_000016.10 (57396076..57416063)

Tissue Specificity

Expressed at high levels in thymus and at low levels in the lung, colon and small intestine.

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Dermatitis
• Cholangiocarcinoma
• Dermatitis, Atopic
• Asthma
• Neoplasms
• Dermatologic Disorders
• Allergy
• Eosinophilia
• Lymphoma
• Pneumonia
• Malignant Neoplasms
• Tissue Adhesions

• Fibrosis
• Contact Dermatitis
• Lung Diseases
• Allergic Asthma
• Hodgkin Disease
• Psoriasis
• Autoimmune Reaction

Interacting Proteins

• CCL21
• CCL25
• CCL26
• CCL28
• CCL5

• CCR4
• CCR5
• PF4

Pathways

• Pathogenesis
• Immune Response
• Secretion
• Chemokine Production
• Chemotaxis
• Sensitization
• Cytokine Production
• Cell Migration
• Hypersensitivity
• Inflammatory Response
• Cell Proliferation
• Localization
• Cell Activation

• Reverse Transcription
• T Cell Proliferation
• Cell Adhesion
• T Cell Activation
• Granuloma Formation
• T Cell Migration
• Platelet Activation

PTMs

• Phosphorylation
• Cleavage
• Nitration

• Citrullination
• Oxidation
• Prenylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CCL17

Boster Bio Anti-Macrosialin CD68

Are you interested in knowing how you can maximize the benefits of Boster Bio's Anti-Macrosialin Antibody CD68? Check out this article for more information on its clinical use and cell-based pathology applications. We'll also talk about the Boster Bio product's credits. Here are a few most compelling reasons for this antibody to be an important tool. Here's what you can do with it.

Boster Bio Anti-Macrosialin Antibody CD68

The Boster Biologicals company develops research antibodies and ELISA kits for the detection of biomarkers within the areas of neurosciences or cancer, as well as development biology. These kits can detect biomarkers down to the picogram level and are extremely sensitive and specific. Boster Bio offers immunological reagents that can be used in research. Boster Bio is one of the leading companies manufacturing antibodies for this biomarker.

Boster Bio CCL17 Marker

The Anti-C-C motif chemokine 17 CCL17 antibody from Boster Bio has been validated for use in ELISA, immunohistochemistry, and IF experiments. This antibody reacts with Rat, Mouse, and Human cells. Its peptide conjugate is labeled with Trehalose and is suitable for various research applications. The Boster C–C motif chemokine 17 antibody is available in many sizes and has been tested on mice, rats and human samples.

Clinical Applications

The CCL17 marker, which is an eosinophil-derived cell cytokine, is a cell cytokine. It binds to CCR4, which is a molecule that is expressed on the surface T-cells. Interestingly, CCL17 is also present in peripheral blood mononuclear cells (PBMCs) upon stimulation. This marker can be used to diagnose and prognost for various ailments.

This chemokine is an important pro-inflammatory cytokine that is found in the human immune system. CCL17 could also be found in thymocytes at maturation and could be important in the development and the maintenance of asthma. The CCL17 marker is present at high levels in sputum and serum of asthmatics. It is also present in the sputum of patients suffering from an atopic skin condition.

A validation group of 58 patients enrolled in this study. Before the onset of COVID-19, patients were assessed. CCL17 was assessed on the first and third days of hospitalization. After all parties had provided written consent the patients were enrolled. CCL17 can be used to distinguish between patients suffering from mild or moderate disease. Furthermore, its clinical value is also valuable in the initial stage of the disease, when CCL17 levels are low.

The incidence of atopic dermatitis among children with KD is nine times greater than that of children who have no KD. They also had a higher incidence for bronchial asthma. Patients with KD had significantly higher levels of CCL17 than the controls. These findings point to a connection between the TARC/CCL17 gene and KD. Atopic dermatitis is a skin condition where CCL17-expressing lymphocytes are identified in biopsies taken of the skin.

Cellular Pathology

Boster Bio first identified the CCL17 marker in the year 2010. In the last three decades, it has evolved into an important diagnostic marker for many illnesses, including leukemia. But, it's underutilized because of its complexity. This new biomarker may be the answer to many of your questions. To answer this question, it's essential to know how the CCL17 marker works.